Background: Double depression (DD), the co-existence of DSM-IV major depressive disorder (MDD) and dysthymia, is a poorly known and sparsely studied phenomenon. Nevertheless, it is prevalent in clinical samples of patients with depression. Thus, it is important to understand the efficacy of its treatment.
Methods: We conducted a meta-analysis of studies in which antidepressant medication was used to treat depression. Systematic searches in bibliographical databases resulted in 11 samples, including 775 patients that met inclusion criteria.
Results: The overall effect size indicating the differences in depressive symptoms before and after pharmacotherapy was 1.81 (95% CI: 1.47, 2.16), suggesting that individuals with depression exhibited a significant reduction in their depressive symptoms following treatment. Importantly, a moderation analysis indicated that a higher proportion of individuals with DD within a sample was associated with lower effect sizes. Publication bias did not pose a major threat to the stability of the findings.
Limitations: High observed heterogeneity indicated substantial variability in effect sizes and elucidation of the potential moderators of treatment outcome was limited due to a paucity of relevant data.
Conclusions: Pharmacotherapy seems to be effective in treating DD, but DD may be more difficult to treat than either MDD or dysthymia alone. More research specifically focusing on the treatment of DD with larger sample sizes using randomized control trials is needed to make a firm conclusion.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.psychres.2020.113262 | DOI Listing |
Front Public Health
January 2025
Department of Health Care Management, School of Information and Management, Guangxi Medical University, Nanning, Guangxi, China.
Background: The aging population presents a significant public health challenge, particularly concerning mental health and injury prevention. Anxiety and depression are common among the older adult, affecting their quality of life and increasing the risk of unintentional injuries (UI). This study aims to explore the association between anxiety and depression and UI risk among the older adult in Guangxi, China, using data from the 2023 National Health Service Survey.
View Article and Find Full Text PDFQual Life Res
January 2025
Eye and Vision Research, Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
Purpose: To assess the relationship between quality of life (QoL) and ocular surface health within a Finnish population-based cohort.
Methods: A cross-sectional study involved 601 individuals born between the years 1933-1956. Ocular surface health and dry eye disease (DED) were clinically evaluated using several diagnostic tests.
BMJ Open
January 2025
Centre for Evidence-Based Chinese Medicine, Beijing University of Chinese Medicine, Beijing, China
Objectives: To assess the therapeutic effects and safety of Tongxie Yaofang (TXYF) granules vs placebo as an alternative treatment for diarrhoea-predominant irritable bowel syndrome (IBS-D). We hypothesised that TXYF would improve clinical responses among patients with IBS-D.
Design: A randomised, double-blind, placebo-controlled, phase II, superiority trial.
Brain Struct Funct
January 2025
Department of Radiology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, 330006, Jiangxi Province, China.
A significant proportion of patients who have recovered from COVID-19 suffer from persistent symptoms, referred to as "post-acute sequelae of SARS-CoV-2 infection (PASC)". Abnormal brain intrinsic activity has been observed in PASC patients, but the patterns of frequency-dependent intrinsic activity in the PASC and non-PASC (recovered COVID-19 patients without persistent symptoms) groups and their association with neuropsychiatric sequelae remain unclear in PASC. Twenty-nine PASC patients, 27 non-PASC subjects, and 31 healthy controls (HCs) were recruited.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!